Ergoteles’s Lunai Bioworks LNAI Stock Holding History

Ergoteles’s Portfolio LNAI Stock Details LNAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-600	Closed	-$238K	–	1594
2021 Q2	$238K	Buy	+600	New	+$196K	0.01%	1190

Other funds holding LNAI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ergoteles's LNAI Position: Q3 2021 in Review

Ergoteles sold out of Lunai Bioworks (LNAI) in Q3 2021, closing a stake of 600 shares — an estimated $238K sold.

Ergoteles first reported a position in LNAI in Q2 2021 and held it in 1 quarter. The position peaked at $238K in Q2 2021. 32 funds tracked by Wall St. Rank hold LNAI as of Q3 2021.

Ergoteles reported no remaining Lunai Bioworks position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 600 Lunai Bioworks shares in Q3 2021, an estimated $238K.
Ergoteles first reported a position in Lunai Bioworks in Q2 2021 and held it in 1 quarter.
Ergoteles's Lunai Bioworks position peaked at $238K in Q2 2021.
32 funds tracked by Wall St. Rank held Lunai Bioworks as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.